Aprea Therapeutics Inc

APRE · NASDAQ · Healthcare / Biotechnology

0.4162USD-0.02 (-5.41%)

Price History

Full chart

Market Stats

Previous Close0.44

Open0.473

Day Range0.4104 – 0.473

52-Week Range0.548 – 1.69

Volume91.08K

Market Cap9.82M

P/E (TTM)0.00

Forward P/E0.00

EPS-0.94

Dividend Yield0.00%

Beta1.63

50-Day Avg0.7198

200-Day Avg0.7944

About

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.

Company Details

SectorHealthcare
IndustryBiotechnology
CEODr. Oren Gilad Ph.D.
Employees8
Headquarters3805 Old Easton Road, Doylestown, PA, United States, 18902, USA
Websitehttps://aprea.com

Leadership

Dr. Oren Gilad Ph.D.Co-Founder, CEO, President & Director · b. 1968
Mr. John P. Hamill CPASenior VP, CFO, Principal Accounting Officer & Secretary · b. 1964
Dr. Lars B. Abrahmsen Ph.D.Senior VP & Chief Scientific Officer · b. 1957
Mr. Brian WileySenior Vice President of Corporate Development & Strategy · b. 1968
Dr. Michel Afargan Ph.D.Head of Pharmacology Development
Mr. Ze'ev Weiss B.Sc., C.P.A.Chief Business Advisor · b. 1962
Dr. Eugene P. Kennedy F.A.C.S., M.D.Chief Medical Advisor · b. 1969
Ms. Andrea EpsteinController

Financials

Income Statement

Currency: USD	2007-12-31	2012-12-31	2013-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	67.87K	0	0	0	0	0	0	0	0	583.23K	1.50M	285.76K
Growth (%)	-	-100.00%	-	-	-	-	-	-	-	-	+157.63%	-80.98%
Cost of Revenue	13.41K	0	0	7.93K	8.32K	170.25K	229.61K	271.68K	16.40M	7.05K	9.36M	21.71K
Gross Profit	54.46K	0	0	-7.93K	-8.32K	-170.25K	-229.61K	-271.68K	-16.40M	576.18K	-7.86M	264.04K
Gross Margin	80.24%	-	-	-	-	-	-	-	-	98.79%	-523.16%	92.40%
Operating Expense	3.22M	21.33K	246.49K	15.84M	16.48M	29.37M	52.58M	37.17M	96.99M	16.05M	6.46M	13.50M
Operating Income	-3.17M	-21.33K	-246.49K	-15.85M	-16.49M	-29.54M	-52.81M	-37.45M	-113.39M	-15.47M	-14.32M	-13.23M
Operating Margin	-4670.09%	-	-	-	-	-	-	-	-	-2652.80%	-953.00%	-4631.12%
EBITDA	-	-	-	-15.18M	-15.52M	-27.89M	-53.25M	-36.86M	-37.37M	-14.28M	-12.94M	-12.58M
EBITDA Margin	-	-	-	-	-	-	-	-	-	-2448.38%	-860.94%	-4401.56%
Net Income	-3.52M	-254.01K	-436.21K	-15.19M	-15.53M	-28.06M	-53.92M	-36.54M	-112.66M	-14.29M	-12.96M	-12.60M
Net Income Margin	-5193.06%	-	-	-	-	-	-	-	-	-2449.59%	-862.43%	-4409.16%
R&D	-	-	-	13.39M	14.19M	20.95M	37.88M	23.90M	92.42M	7.63M	9.36M	7.04M
R&D as % of Total Revenue	-	-	-	-	-	-	-	-	-	1307.80%	623.16%	2464.68%
Interest Expense	0	0	0	15	182	156.35K	222.65K	1.65K	448.67K	-	-	-
Interest Expense % of Total Revenue	0.00%	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

Currency: USD	2007-12-31	2012-12-31	2013-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	315.47K	-	-	24.76M	66.02M	133.61M	92.81M	56.82M	30.16M	22.65M	23.98M	15.93M
Total Liabilities	2.43M	5.26M	5.70M	60.53M	117.46M	9.36M	15.41M	7.32M	4.51M	4.39M	4.67M	3.49M
Total Equity	-2.11M	-	-	-35.77M	-51.44M	124.24M	77.40M	49.51M	25.64M	18.26M	19.31M	12.44M
Cash	3.12K	-	-	24.40M	65.68M	130.09M	89.02M	53.08M	28.79M	21.61M	22.85M	14.60M
Total Debt	-	-	-	-	-	544.95K	335.16K	190.47K	-	-	-	-
Net Debt	-	-	-	-24.40M	-65.68M	-129.54M	-88.68M	-52.89M	-28.79M	-21.61M	-22.85M	-14.60M

Cash Flow

Currency: USD	2007-12-31	2012-12-31	2013-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-1.90M	-	-	-14.00M	-15.25M	-26.71M	-41.80M	-37.69M	-25.01M	-12.18M	-13.56M	-12.89M
Investing Cash Flow	-	-	-	-3.70K	-3.70K	-30.90K	-25.71K	-	-	-93.09K	-15.48K	-
Financing Cash Flow	1.72M	-	-	23.34M	56.37M	92.58M	150.95K	1.75M	682.97K	5.14M	14.82M	4.64M
Capital Expenditure	0	0	0	3.70K	3.70K	30.90K	25.71K	0	0	93.09K	15.48K	0
Free Cash Flow	-	-	-	-14.00M	-15.25M	-26.74M	-41.83M	-37.69M	-25.01M	-12.27M	-13.57M	-12.89M
Dividends Paid	-	-	-	0	0	-	-	-	-	-	-	-
FCF to OCF	-	-	-	100.00%	100.02%	100.12%	100.06%	100.00%	100.00%	100.76%	100.11%	100.00%
Dividend Paid to FCF	-	-	-	0.00%	0.00%	-	-	-	-	-	-	-

Earnings

Report Date	Aug 28, 2019	Nov 14, 2019	Mar 26, 2020	May 15, 2020	Aug 11, 2020	Nov 5, 2020	Mar 16, 2021	May 6, 2021	Aug 12, 2021	Nov 8, 2021	Mar 15, 2022	May 16, 2022	Aug 11, 2022	Nov 9, 2022	Mar 30, 2023	May 15, 2023	Aug 10, 2023	Nov 9, 2023	Mar 26, 2024	May 14, 2024	Aug 12, 2024	Nov 7, 2024	Mar 25, 2025	May 12, 2025	Aug 12, 2025	Nov 12, 2025	Mar 16, 2026	May 13, 2026	Aug 12, 2026	Nov 11, 2026
EPS Estimate	0.00	-78.87	-8.00	-11.35	-12.05	-15.20	-12.85	-9.85	-9.35	-9.05	-8.80	-7.60	-6.20	-1.60	-3.08	-0.82	-1.38	-1.04	-0.77	-0.80	-0.60	-0.74	-0.54	-1.00	-0.71	-0.34	-0.36	-0.23	-0.22	-0.08
EPS Actual	-0.31	-105.80	-12.80	-9.00	-15.60	-11.60	-14.60	-9.20	-9.60	-9.00	-7.20	-7.20	-19.63	-2.40	-0.92	-1.34	-0.87	-0.86	-0.92	-0.67	-0.58	-0.64	-0.49	-0.66	-0.53	-0.47	-0.32	-0.22	-0.07	-
Surprise	-	-34.14%	-60.00%	20.70%	-29.46%	23.68%	-13.62%	6.60%	-2.67%	0.55%	18.18%	5.26%	-216.61%	-50.00%	70.13%	-63.41%	36.96%	17.31%	-19.48%	16.25%	3.33%	13.51%	9.26%	34.39%	25.35%	-38.24%	11.11%	4.35%	68.18%	-
Timing	-	After-hours	Pre-market	Pre-market	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	Pre-market	After-hours	After-hours	After-hours	After-hours	Pre-market	After-hours	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	-	Pre-market	-

Key Statistics & Ratios

Market Cap9.82M

Enterprise Value-31.41M

Trailing P/E0.00

Forward P/E0.00

Price / Sales1893.41

Price / Book0.26

EPS-0.94

Book Value3.11

Revenue (TTM)5.18K

Gross Profit (TTM)-6.72M

EBITDA-13.20M

Profit Margin0.00%

Operating Margin-255025.51%

Return on Equity-46.15%

Return on Assets-27.73%

Shares Outstanding12.59M

Shares Float7.91M

Beta1.63

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Analyst Ratings

Buy

Based on 3 analystsTarget 3.73

Strong Buy
1
Buy
2

Ownership Breakdown

Institutions: 18.83%
Insiders: 9.17%
Retail / Other: 72.00%

Top Institutional Holders

AIGH Capital Management, LLC
1.02M8.07%
Vestal Point Capital LP
350.00K2.78%
Sphera Funds Management Ltd.
270.00K2.14%
Nantahala Capital Management, LLC
205.76K1.63%
Geode Capital Management, LLC
119.13K0.95%
Scientech Research LLC
60.28K0.48%
Citadel Advisors Llc
58.60K0.47%
Diadema Partners LP
44.91K0.36%
BNP Paribas Arbitrage, SA
39.82K0.32%
Vanguard Fiduciary Trust Co
38.46K0.31%
Renaissance Technologies Corp
25.10K0.20%
Morgan Stanley - Brokerage Accounts
22.33K0.18%
LPL Financial Corp
21.05K0.17%
Vanguard Capital Management, LLC
19.62K0.16%
HighTower Advisors, LLC
13.86K0.11%
TWO SIGMA SECURITIES, LLC
13.50K0.11%
Susquehanna International Group, LLP
13.02K0.10%
BlackRock Inc
8.50K0.07%

Top Fund Holders

Fidelity Extended Market Index
59.94K0.48%
Fidelity Total Market Index
7.20K0.06%

Stock Splits

Feb 13, 20231:20